<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998385</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2016-02</org_study_id>
    <nct_id>NCT02998385</nct_id>
  </id_info>
  <brief_title>Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)</brief_title>
  <acronym>SANTAL</acronym>
  <official_title>A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III, multicenter, randomized, open-label, french study comparing:&#xD;
&#xD;
        -  Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction)&#xD;
           (IMRT or protontherapy)&#xD;
&#xD;
        -  Arm B: Radiotherapy (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction; IMRT&#xD;
           or protontherapy) + concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 cycles)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carcinomas of the sinuses and the salivary glands are rare. They are heterogeneous in terms&#xD;
      of anatomical sites and histology subtypes. For this reason and in the absence of prospective&#xD;
      study, their treatment is still largely extrapolated from data of frequent carcinomas of the&#xD;
      upper digestive tract. These tumors are most often diagnosed lately. Their treatment is based&#xD;
      on a multimodal management of care, with a central place for the surgery and radiotherapy&#xD;
      (Proof level Grade C). Despite the advances in surgical techniques, and the addition of&#xD;
      radiation therapy, the 5-year overall survival probability does not exceed 65% mainly due to&#xD;
      a loco regional development.&#xD;
&#xD;
      In this context, a chemotherapy administered concomitantly to radiotherapy, could increase&#xD;
      the efficacy of the locoregional treatment by a radiosensibilization process and regardless&#xD;
      of the histology. This point is regularly discussed in multidisciplinary concertation&#xD;
      meeting, including bi-monthly national REFCOR meeting (network of French Expertise on rare&#xD;
      Cancers of the head and neck). At present, the lack of data brings even to discuss the&#xD;
      addition of cisplatin to exclusive irradiation of unresectable or not operable tumors.&#xD;
&#xD;
      No randomized study has been published in this context. The first comparative prospective&#xD;
      study addressing the addition of weekly cisplatin to the adjuvant irradiation of salivary, is&#xD;
      a phase II randomized study (Radiation Therapy Oncology Group - RTOG 1008) currently&#xD;
      enrolling patients in the United States of America.&#xD;
&#xD;
      The Sponsor propose to conduct a phase III randomized study evaluating the impact of the&#xD;
      addition of cisplatin to a treatment by radiotherapy in adjuvant setting (≥ 65 Gy) in case of&#xD;
      a high risk of recurrence: case of radioresistant histologies (e.g. cystic fibrosis adenoids&#xD;
      carcinomas), or case of unfavourable histo-prognostic criteria (incomplete resection,&#xD;
      presence of emboli, etc.) in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomization to date of disease progression or death, which occur first, assessed during 62 months</time_frame>
    <description>Compare progression-free survival between the 2 treatment arms: radiation therapy alone versus radiochimiotherapy in adjuvant patients treatment operated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization to date of death, assessed during 62 months</time_frame>
    <description>Compare the 2 arms of treatment in operated patients in terms of overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of quality of Life: QLQC30 overall score</measure>
    <time_frame>From date of randomization to end of study or death or progression (the first occurred), assessed during 62 months</time_frame>
    <description>Compare quality of life (QLQC30 overall score) between arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A&#xD;
Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.&#xD;
Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy + concomitant cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B Concomitant systemic treatment with cisplatin + radiotherapy&#xD;
According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).&#xD;
Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.&#xD;
Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>intravenous, concomitant to irradiation</description>
    <arm_group_label>Radiotherapy + concomitant cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week</description>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_label>Radiotherapy + concomitant cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Resected tumors of the sinus or the salivary glands T3-4, N1-3 or T1-2 N0, with overgrown&#xD;
        banks or positive margins (&lt; 5 mm)&#xD;
&#xD;
        or&#xD;
&#xD;
        Unresectable or not operable tumors of salivary glands or sinuses&#xD;
&#xD;
        - Carcinomas of the major salivary glands (Parotid, submandibular and sublingual glands)&#xD;
        and accessories with the following histologies: adenoid cystic Carcinoma, adenocarcinoma&#xD;
        without another indication (SAI) of high-grade, muco-epidermoid of intermediate grade or&#xD;
        high grade Carcinoma, salivary ductal carcinoma, carcinomas to turn cells (with&#xD;
        dedifferencie contingent or Ki 67 &gt; 10%), Sebaceous Carcinoma, large cell carcinoma, small&#xD;
        cell carcinomas Mucinous adenocarcinoma, carcinoma on massively invasive Pleomorphic&#xD;
        adenoma, oncocytic carcinomas, myoepithelial Carcinoma&#xD;
&#xD;
        or&#xD;
&#xD;
        Malignant tumors of the sinus with the following histology: adenocarcinomas of the ethmoid&#xD;
        (ADE) of bowel and no intestinal type, CF adenoids carcinomas and other carcinomas of&#xD;
        salivary origin (COS).&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Performance status 0 -2 (WHO criteria)&#xD;
&#xD;
          -  For patients ≥ 70 years, the score to the G8 questionnaire must be &gt; 14 with no fall&#xD;
             in the previous 12 months or with a geriatric assessment consistent with the&#xD;
             administration of chemotherapy&#xD;
&#xD;
          -  Estimated life expectancy greater than or equal to 6 months&#xD;
&#xD;
          -  Neutrophils &gt; 1.5 x 109/l, platelets &gt; 100 x 109/l, hemoglobin ≥ 9.5 g/dl, bilirubin ≤&#xD;
             3 x upper normal value (ULN), AST/ALT &lt; 5 ULN, PAL &lt; 3 ULN&#xD;
&#xD;
          -  Creatinin Clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Adequate cardiac function according to the investigator, compatible with the&#xD;
             administration of cisplatin 100 mg/m²&#xD;
&#xD;
          -  Affiliation to a social insurance or beneficiary of such a regimen&#xD;
&#xD;
        Patient having given his written consent signed before any study specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of radiation therapy in the ENT area&#xD;
&#xD;
          -  Synchronous metastases&#xD;
&#xD;
          -  Contraindications for administration of cisplatin or carboplatin&#xD;
&#xD;
          -  Allergy to cisplatin and/or its excipients&#xD;
&#xD;
          -  Melanoma, lymphoma, tumors of mesenchymal (of type Sarcoma), epidermoid carcinomas,&#xD;
             (SCUNC) neuroendocrine carcinomas and carcinoma undifferentiated (SNUC),&#xD;
             nasopharyngeal carcinomas type 1, 2, and 3.&#xD;
&#xD;
          -  Vaccination against yellow fever, recent or planned&#xD;
&#xD;
          -  Administration of phenytoin with prophylactic purpose&#xD;
&#xD;
          -  Other cancer, except for cancer in situ of the cervix, skin Carcinoma (except&#xD;
             melanoma) or cancer controlled for more than 5 years&#xD;
&#xD;
          -  Pregnant, breastfeeding or without birth control woman. Woman having the ability to&#xD;
             procreate should have (serum or urinary) negative pregnancy test within 14 days prior&#xD;
             to study treatment decision-making. (Men or women) patients should use a reliable&#xD;
             contraceptive method throughout the treatment and at least 6 months after the end of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Persons deprived of liberty under supervision or under curatorship, or unable to&#xD;
             adhere to medical follow-up of the study for geographical, social or psychological&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François Régis FERRAND, MD</last_name>
    <phone>+33 1 43 98 50 78</phone>
    <email>francoisregisferrand@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliette THARIAT, Prof</last_name>
    <phone>+33 06 45 53 98 01</phone>
    <email>j.thariat@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Bégin</name>
      <address>
        <city>Saint-Mandé</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Régis FERRAND, MD</last_name>
      <email>francoisregisferrand@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas MEERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salivary glands</keyword>
  <keyword>sinus carcinoma</keyword>
  <keyword>radiochemotherapy concomitant</keyword>
  <keyword>cisplatin</keyword>
  <keyword>protontherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nose Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

